Sugi Predict

Sugi Predict / Compounds / SCHEMBL7073134

SCHEMBL7073134

SCHEMBL7073134

CC(=N)Nc1ccc2[nH]c(C(C)c3nc4ccc(C(=O)NCCOc5ccccc5C(=O)O)cc4n3C)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.38
▸ TPSAB1 Q15661 3/20 0.37
▸ TPSD1 Q9BZJ3 3/20 0.37
▸ TPSG1 Q9NRR2 3/20 0.37
▸ NPC1 O15118 2/20 0.35
▸ ACSS2 Q9NR19 6/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ PAX8 Q06710 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072722 0.94 MAPT (0.38) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7072013 0.94 MAPT (0.37) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7071802 0.89 TPSAB1 (0.37) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7073156 0.89 NPC1 (0.38) TPSAB1TPSD1TPSG1NPC1ACSS2
SCHEMBL7405580 0.89 TPSAB1 (0.40) TPSAB1TPSD1TPSG1NPC1ACSS2
SCHEMBL7072630 0.89 TPSAB1 (0.44) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7397634 0.89 L3MBTL1 (0.41) TPSAB1TPSD1TPSG1NPC1ACSS2
SCHEMBL7067665 0.87 TPSAB1 (0.36) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7067761 0.86 TPSAB1 (0.35) MAPTTPSAB1TPSD1TPSG1NPC1
SCHEMBL7073172 0.86 ACSS2 (0.39) MAPTTPSAB1TPSD1TPSG1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 — — US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 — — US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 — — US disclosed
EP-1019382-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS, INC. (US) 2000-07-19 — — EP disclosed
WO-1998045275-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS CORPORATION (US) 1998-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 MAPT 2104/4885TPSAB1 5/4885TPSD1 6/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 MAPT 2289/4885TPSAB1 5/4885TPSD1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.